Did the widespread use of long-acting calcium antagonists decrease the occurrence of variant angina?

Shozo Sueda1, Hiroaki Kohno, Hiroshi Fukuda

  • 1Department of Cardiology, Saiseikai Saijo Hospital, Tsuitachi 269-1, Saijo City, Ehime Prefecture, Japan 793-0027. EZF03146@nifty.or.jp

Chest
|December 11, 2003
PubMed

Insights

Variant angina (VA) frequency has decreased, likely due to increased use of long-acting calcium antagonists (L-CAs). This study retrospectively examined VA cases, finding a significant decline in recent years.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Variant angina (VA) prevalence has appeared to decline with the widespread adoption of long-acting calcium antagonists (L-CAs).
  • Retrospective analysis of VA frequency is crucial for understanding its current clinical significance.

Purpose of the Study:

  • To investigate the changing frequency of variant angina (VA) over a 12-year period.
  • To correlate observed trends with therapeutic interventions, particularly calcium antagonist use.

Main Methods:

  • Retrospective analysis of 349 patients with angiographically confirmed coronary spastic angina (CSA) from 1991-2002.
  • Classification of patients into four 3-year periods to assess temporal trends in VA and treatment modalities.
  • Spasm provocation tests were used for diagnosis, with VA defined by ST elevation during attacks or stress tests.

Main Results:

  • The overall ratio of VA to CSA significantly decreased over the study period (32% to 5%).
  • While CSA diagnosis frequency remained stable, the number of VA cases and the VA/CSA ratio declined significantly in later years.
  • Administration of L-CAs increased substantially in the latter half of the study, correlating with the decrease in VA.

Conclusions:

  • The frequency of variant angina (VA) has demonstrably decreased in Japan.
  • Widespread therapeutic use of long-acting calcium antagonists (L-CAs) is a likely contributing factor to this observed decline.
Abstract

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...